Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BKM120 and Panitumumab in RAS-Wild Type Colorectal Cancer
NCT01591421Phase 2Completed
- Sponsor
- Canadian Cancer Trials Group
- Start
- Sep 2012
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of buparlisib in colorectal cancer (metastatic) (mCRC) and colorectal cancer (CRC), sponsored by Canadian Cancer Trials Group. Started Sep 2012; status: completed.
02
Drugs
buparlisib
03
Conditions
colorectal cancer (metastatic) (mCRC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT01591421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01591421.